- Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
- Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
- Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
- PMID: 36261688
- PubMed abstract
- Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
- Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
- JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
- PMID: 36265114
- PubMed abstract
- Source abstract
- SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
- Flaherty C, DiSilvestro PA.
- OncLive. 2022 Oct 20.
- Review. Interview.
- Free Full Text
Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)
- Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
- O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
- Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
- PMID: 36260241
- PubMed abstract
- Source abstract
- Population genomic screening: Ethical considerations to guide age at implementation.
- Spencer SJ, Fullerton SM.
- Front Genet. 2022 Oct 4;13:899648. doi: 10.3389/fgene.2022.899648.
- PMID: 36267415
- PubMed abstract
- Review
- Free Full Text